Inve US ▾
SOSOLV

Solventum (SOLV) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 5, 2026

Source: earnings call transcript

Executive summary

Solventum Q2 FY26 — Strong Performance and Strategic Portfolio Optimization

Solventum delivered a strong second quarter, surpassing top and bottom-line expectations, driven by solid execution and momentum across all segments. The company is nearing completion of its 3M separation, which is expected to improve free cash flow and focus resources on growth. A significant strategic move was announced with the intent to separate the Health Information Systems (HIS) business to unlock shareholder value and sharpen the company's focus on MedTech, with an Investor Day planned for Q1 next year to detail the post-HIS long-range plan.

Highlights

5

  • Organic sales growth of 9.5% reported, or 4% normalized for ERP advanced orders, exceeding expectations.

  • Adjusted EPS of $2.55, including $0.34 from advanced orders and $0.48 from tariff refund, ahead of expectations.

  • Gross margins increased by 410 basis points to 60.1% (55.6% excluding tariff refund), driven by programmatic savings.

  • Acera acquisition continues to perform strongly with over 40% year-over-year revenue growth and over 80% gross margin.

  • Share repurchase program accelerated, with $288 million used to repurchase nearly 4 million shares in the quarter.

Concerns

3

  • ERP advanced orders of approximately $125 million in Q2 will mostly reverse in Q3, leading to an expected Q3 sales decline of -3% to -4%.

  • Tariff impact of 150 basis points on gross margins, partially offset by programmatic savings.

  • Litigation costs of $157 million (net of $55 million insurance proceeds) recorded, excluded from non-GAAP results.

Guidance & targets

CategoryTargetConfidence
Full-year 2026 Organic Sales Growth
2.5% to 3%
high materiality
High
Full-year 2026 Organic Sales Growth (ex-SKU exits)
3.5% to 4%
high materiality
High
Full-year 2026 Currency Impact on Sales Growth
approximately 100 basis points favorable
medium materiality
High
Full-year 2026 Operating Margin
22.2% to 22.7%
high materiality
High
Full-year 2026 Nonoperating Expenses
approximately $300 million
medium materiality
High
Full-year 2026 Effective Tax Rate
19.5% to 20.5%
medium materiality
High
Full-year 2026 Tariff Impact
neutral impact
medium materiality
High
Full-year 2026 Earnings Per Share
$7.10 to $7.20
high materiality
High
Full-year 2026 Free Cash Flow
$200 million to $300 million
high materiality
High
Q3 2026 Sales Impact from Advanced Orders Reversal
minus 3% to minus 4% range
high materiality
High
Q3 2026 EPS Impact from Advanced Orders Reversal
minus $0.34
high materiality
High
Q4 2026 Sales Growth Expectation
3% to 4% range
medium materiality
High
2027 Organic Sales Growth (ex-SKU exits)
accelerate past 3.5% to 4%
high materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
MedSurg
Growth driven by ERP advanced orders, particularly in Infection Prevention and Surgical Solutions, and continued benefit in Advanced Wound Care from performance and advanced orders. Acera contributed $32 million to reported sales.
ERP advanced orders contribution: 700 basis pointsAdvanced Wound Care organic growth: 7.1%Infection Prevention and Surgical Solutions organic growth: 10.1%
$1.4B8.9% organic——
Dental Solutions
Underlying performance benefited from innovative new product launches, alongside a significant contribution from ERP advanced orders.
ERP advanced orders contribution: approximately 10 percentage points
$396M15.2% organic——
Health Information Systems
Growth driven by continued strength in revenue cycle management solutions, supported by healthy customer retention and ongoing commercial execution.
$354M5.4% organic——

SOLV operating KPIs by quarter

SOLV operating KPIs stated on its earnings calls, by fiscal quarter
KPI Dec 2025 Q4 FY25 Mar 2026 Q1 FY26Change vs prior quarter
Distribution centers
55 Regarding supply chain, we've taken further steps to separate from 3M and have now reduced our distribution center network to 55 locations, progressing towards our goal of 45. Source: earnings call transcript
54 With further work to streamline our distribution centers, we are now down to 54 worldwide. Source: earnings call transcript
-1.8%

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Product announcements

ProductTypeDetails
V.A.C. Peel and Place dressinglaunch
Attest sterilization productslaunch
Tegaderm CHG global expansionexpansion
ClinPro Clearlaunch
Filtek Easy Match and Easy Match Flowablelaunch
Composite warmerlaunch
Clarity aligner attachmentslaunch
AI-driven autonomous coding applicationslaunch

Deals & partnerships

Acera Acquisition of a company with innovative synthetic tissue matrix technology (Restrata).

First acquisition for Solventum, integrated and exceeding expectations. Integration activities remain on track with several key system conversions complete.

Health Information Systems (HIS) business Advancing the separation of the Health Information Systems business to maximize value.

Strategic decision to separate HIS, which is a differentiated, trusted business with a highly resilient financial profile, to better capitalize on AI advancements. Solventum is open to various separation methods (spin or sale) and use of proceeds to maximize value.

Purification and Filtration business Divestiture of the Purification and Filtration business.

Divestiture activities continue to progress according to plan, including transition-related work streams supporting separation.

Risks & headwinds

ERP cutover complexity and distraction Q2-Q3 FY26

Advanced orders of approximately $125 million in Q2 to mitigate disruption; Q3 sales expected to be -3% to -4% due to reversal.

Mitigation:Planned temporary advanced ordering; nearing completion of ERP cutovers to free up talent and resources.

SKU rationalization plan headwinds FY26

Approximately 100 basis points impact on Q2 organic growth.

Mitigation:Part of a strategic plan, expected to be a 100 basis point impact for the full year, but will not have an impact in 2027.

Tariff impact on gross margins Q2 FY26

150 basis points impact on gross margins (ex-tariff refund).

Mitigation:Partially offset by programmatic savings and portfolio optimization. Full-year tariff impact now expected to be neutral due to Q2 refund.

Litigation costs Q2 FY26

$157 million recorded (net of $55 million insurance proceeds).

Mitigation:Excluded from non-GAAP operating income and EPS; insurance proceeds received.

Temporary demands on cash flow from separation activities FY26

Despite strong underlying cash generation, separation-related activities create temporary demands on cash flow.

Mitigation:Meaningful improvement expected as separation-related costs decline beginning in Q4.

Potential EPS dilution from HIS separation Future

Not quantified, but acknowledged as a factor.

Mitigation:Company aims to minimize dilution and maximize shareholder value by carefully selecting the separation method and use of proceeds (e.g., share buybacks).

What to watch in Q3 FY26

HIS Separation Progress

Future date, Investor Day in Q1 next year.
Current Intent to separate announced; early in process.
Target Further updates on method, timeline, and financial impact.

Why it matters

This is a major portfolio optimization move expected to unlock shareholder value and redefine Solventum as a focused MedTech company.

We'll update you on the financial impact of the expected separation at a future date.

Find out whether SOLV delivers this. Inve re-checks your case every morning.

Q&A highlights

Asked about external interest in HIS, the stage of the separation process, and how HIS separation aligns with a 'stronger growth profile' given its current performance.

Bryan Hanson stated that HIS, despite its strong current performance and growth, has significant untapped potential, especially in AI-driven autonomous coding, which could be better realized with different investment levels and pace of innovation outside Solventum or with a scaled HIT player. He confirmed the company is early in the separation process, driven by the lifting of spin-off barriers and market changes. Inbound interest has been ongoing and is expected to increase.

“We see significant opportunity. Just think about it. If you think about autonomous coding, as a revolution, if you will, inside of revenue cycle management. It is just beginning. There is no question about that. But to be able to truly maximize it, we're going to have to see a different investment level. We're going to have to see a different pace of innovation.”

asked by Jason Bednar · answered by Bryan Hanson

2 min read 5 chapters

Detailed narrative

Health Information Systems (HIS) Separation

Solventum announced its intent to separate the Health Information Systems (HIS) business, aiming to maximize shareholder value. The rationale includes strategic fit, as HIS is believed to create greater value outside Solventum, either independently or with a scale player, especially given rapid AI advancements. The separation will allow Solventum to become a more focused MedTech company, concentrating on MedSurg and Dental. The company is early in the process and open to various separation methods (spin or sale) to maximize value, noting that HIS is not highly integrated with the rest of the business, making separation relatively easier.

ERP Cutover and 3M Separation Nearing Completion

The company is in the final steps of its separation from 3M, with the final phases of ERP cutover in motion. Approximately 70% of 200 transition service agreements have been exited, on pace for 90% by year-end 2026. About 950 of 1,200 systems have been migrated, including most ERP implementations. This completion is expected to remove significant complexity, free up talent for innovation and margin expansion, and meaningfully improve free cash flow, transitioning the company from a separation-distracted environment to full operating mode.

Acera Acquisition Exceeding Expectations

Acera, Solventum's first acquisition, continues to perform exceptionally well, with year-over-year revenue growth above 40% and gross margin above 80%. The acquisition aligns with Solventum's M&A playbook, focusing on differentiated technology in known spaces with existing customer relationships. The company expects Acera to remain a double-digit grower and increasingly contribute to overall portfolio growth, highlighting the success of its tuck-in acquisition strategy.

Growth Drivers and Innovation Strategy

Solventum's strategy is centered on five growth drivers in durable markets with attractive growth and margin profiles, representing a multibillion-dollar opportunity. Innovation and commercial teams are aligned with these drivers. Examples include IV site management (Tegaderm CHG), negative pressure wound therapy (V.A.C. Peel and Place), sterilization assurance (Attest products), core restorative and aesthetics in Dental (ClinPro Clear, Filtek Easy Match), and AI-driven autonomous coding in HIS. The vitality index is improving, with almost 20 new products expected to launch by Q1 2028.

Market Utilization and Procedure Trends

Management noted that they are not currently seeing any softness in procedures or business momentum, despite some conflicting reports in the broader market. The company operates across both inpatient and outpatient settings (including ASCs) for many of its MedSurg products, mitigating the impact of any shifts in care settings. This stable market environment, coupled with strong execution, contributes to the company's confidence in its performance.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.